Phase 2 trial in 1800 females aged 9-45 (vaccine vs placebo, 2:1): the quadrivalent HPV 6/11/16/18 vaccine gave seroconversion of 99.7-100% in seronegative participants, and 9-17-year-olds were non-inferior to 18-45-year-olds; no vaccine-related serious events.
RCTn = 1,800
Yang et al. Immunogenicity and safety of a quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha): A randomized controlled phase 2 non-inferiority clinical trial